Rezolute, Inc. (RZLT): R&D Expense
$53.80M
Year ended 2026-06-30
+7.1%
3-year compound annual growth
+29.1%
5-year compound annual growth
+19.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $53.80M | -12.6% | 2026-09-24, From 2025-07-01 |
| 2025-06-30 | $61.53M | +10.4% | 2026-09-24, From 2024-07-01 |
| 2024-06-30 | $55.74M | +27.2% | 2025-09-17, From 2023-07-01 |
| 2023-06-30 | $43.81M | +34.9% | 2024-09-19, From 2022-07-01 |
| 2022-06-30 | $32.49M | +116.8% | 2023-09-14, From 2021-07-01 |
| 2021-06-30 | $14.99M | +3.7% | 2022-09-15, From 2020-07-01 |
| 2020-06-30 | $14.45M | -24.3% | 2021-09-15, From 2019-07-01 |
| 2019-06-30 | $19.08M | +10.4% | 2020-10-13, From 2018-07-01 |
| 2018-06-30 | $17.28M | +42.9% | 2019-09-10, From 2017-07-01 |
| 2017-06-30 | $12.09M | +28.0% | 2018-10-15, From 2016-07-01 |
| 2016-06-30 | $9.45M | +101.0% | 2017-09-22, From 2015-07-01 |
| 2015-06-30 | $4.70M | n/m | 2016-09-28, From 2014-07-01 |
| 2014-06-30 | $34.3K | +882.2% | 2015-09-28, From 2013-07-01 |
| 2013-06-30 | $3.5K | n/a | 2014-09-30, From 2012-07-01 |
| 2012-06-30 | $0 | n/a | 2012-11-09, From 2011-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rezolute, Inc. (RZLT) | 2026-06-30 | $53.80M | -12.6% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $18.11M | +26.1% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $39.05M | +1.6% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $69.88M | +19.4% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $48.94M | +181.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
Compare RZLT, KRRO, MIST, RFL side by side · Screen every company in Pharmaceutical Preparations ↗